Optimapharm, a clinical research organization (CRO) in Europe, has acquired the boutique Swiss CRO Denothex, strengthening its presence in European markets particularly in France, Germany, Switzerland, Spain and Italy.
 
Denothex manages clinical trials of all phases across Europe and Israel, with particular focus on biotechnology and medical devices in oncology.
 
By consolidating Denothex, Optimapharm says it is becoming one of the leading mid-size CRO companies in Europe. Optimapharm was established in Zagreb, Croatia, and operates through offices in 14 European countries. The company has the expertise to conduct phase I – IV clinical research across Europe with a very strong footprint in Central and Eastern Europe.
 
“The clinical research market is experiencing a continued rise, and our goals grow with it. With the combination of continuous organic growth and targeted investments into complementary organizations, we  have very successfully established ourselves as one of the leading players in the field of clinical research in Europe,” said Gordana Gregurić Čičak, chief executive officer, Optimapharm. “We have a proven track record and continue to identify market opportunities and realize acquisitions with a successful integration in order to create more value for our clients, employees and shareholders. We are enthusiastic about the acquisition of Denothex, which further strengthens our oncology and medical device expertise.”
 
In late  2017 Optimapharm successfully acquired and consolidated the Czech company MKS Research, and in November of 2018 attracted a EUR 10 million investment by the Accession Mezzanine Capital fund.
 
“We have become part of an ambitious fast-growing company with well-structured study operations support and services. The integration with Optimapharm provides our customers with  broader access to clinical study centers and patients. We very much look forward to becoming part of such a  prosperous organization“ said Dr. Marc Salzberg, Chairman of Denothex.